Risk factor | Points | |
---|---|---|
Congestive heart failure | 1 | |
Hypertension | 1 | |
A2ge ≥ 75 years | 2 | |
Diabetes | 1 | |
Earlier S2troke or TIA | 2 | |
Vascular disease* | 1 | |
Age 65-74 years | 1 | |
Sex category female, when age ≥ 75 years | 1 |
Maximum score is 9, since the age provides 1 or 2 points. The recommendation on selecting antithrombotic therapy based on the score is displayed in image . The risk factors marked with red colour cannot be affected, but the risk associated with other factors can be reduced by good management of these. * Earlier myocardial infarction, coronary artery disease, aortic arch plaque or severe periferal arterial disease 1 In this modified version of the score, female sex gives one point only if age is ≥ 75 years, allowing the use of identical cut-off values for both men and women. | ||||||||||||||||||||||||
Assessment of bleeding risk by HAS-BLED score. Each item provides 1 point. Bleeding risk is high if the total score is at least 3. Source: Current Care Guideline on atrial fibrillation (Finland, 2021, modified).
| ||||||||||||||||||||||||
The risk factors marked with red colour cannot be affected, but the risk associated with other factors can be reduced in most cases by good management of these. Bleeding risk is increased if the total score is at least 3. * Cancer, anaemia, thrombocytopenia, platelet dysfunction, earlier bleeding | ||||||||||||||||||||||||
Implementation of anticoagulant therapy
Dosage of anticoagulants
Apixaban Factor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Embolism in Patients with Atrial FibrillationDabigatran Dabigatran Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation
Rivaroxaban Factor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Embolism in Patients with Atrial Fibrillation
Warfarin Warfarin for Preventing Stroke in Patients with Non-Valvular Atrial Fibrillation and No History of Cerebral Ischaemia
Aspirin (ASA) and other antiplatelet drugs Antiplatelet Therapy for Patients with Non-Valvular Atrial Fibrillation, Warfarin or Antiplatelet Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
Choosing between direct anticoagulants and warfarin Direct Oral Anticoagulants Versus Vitamin K Antangonists in Non-Valvular Atrial Fibrillation, Factor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Embolism in Patients with Atrial Fibrillation, Dabigatran Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation, Direct Oral Anticoagulants Versus Warfarin Among Atrial Fibrillation Patients with Chronic Kidney Disease, Noac Versus Warfarin Postpci in Atrial Fibrillation
The benefits and disadvantages of direct anticoagulants compared with warfarin. Source: Current Care Guideline on atrial fibrillation (Finland, 2021).
Occlusion of atrial appendage
Anticoagulation during cardioversion for acute AF
References
|